Montemax 10mg ATCO tablets treat chronic bronchial asthma (1 blister x 14 tablets)

Dosage form Box of 1 blister x 14 tablets
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	10mg

Uses

indications

Montemax 10mg drug is indicated for the following cases:

Treatment of chronic bronchial asthma for children (5 mg tablets) and adults (10 mg tablets), including preventing day and night symptoms.

Pharmacology

Montelukast blocks the cysteinyl leuko-triiene receptors of the respiratory tract, thus inhibiting the bronchial spasm due to inhaled LTD4 substances when asthma. The dose of less than 5 mg has an effect on bronchospasm caused by LTD4. In a diagonal study, the placebo is controlled (n = 12), Montelukast prevents bronchospasm at an early and late stage caused by antigens of 75% and 57% respectively.

The effect of Montemax 10mg on leukemia and EOSIN in peripheral blood has been studied in many clinical trials in asthma patients from 2 years old and older using Montemax. Eosin leukemia in peripheral blood decreased by an average of 9-15% compared to placebo, over time for double blindness. In patients with seasonal allergic rhinitis aged 15 and older using Montemax 10mg, Eosin leukocytes in the peripheral blood increased by an average of 0.2% compared to 12% in placebo patients, over the time of double blindness.

This treatment reflects the average difference of 12.3% in the value of Montemax 10mg. The relationship between these observations and the clinical benefits of Montelukast has been mentioned in unknown clinical studies.

Pharmacokinetics

absorption

Montelukast is quickly absorbed after drinking. In adults, after chewing 5 mg tablets at hunger, the average cmax is achieved within 2 - 2.5 hours. The average bioavailability when drinking at hunger is 73% compared to 63% when taken at the same time with the standard meal in the morning. The safety and effectiveness of Montemax 10 mg chewing tablets in the evening to treat asthma has been confirmed through clinical trials and is not related to meals.

Distribution

over 99% Montelukast is attached to plasma proteins. The stable distribution volume of Montelukast on average 8 - 11 liters. Research on rats with Montelukast is marked with radiation found that the distribution through the brain barrier is very small. In short, the concentration of substances marked radioactive at the time after 24 hours is very small in other tissues.

Metabolism

Montelukast is completely metabolized. In tests at the dose of treatment, Montelukast's metabolic substances are not found in plasma and older patients. In vitro studies use human liver targets that Cytochrome P450 3A4 and 2C9 participated in the metabolism of Montelukast. Clinical studies have detected the effects of known cytochrome P450 3A4 receptors (such as ketoconazole, erythromycin) or 2C9 (such as fluconazole) does not affect Montelukast's kinetic dynamics.

Based on the next in vitro studies on human liver mini, Montelukast's therapeutic concentration in non -inhibited plasma Cytochrome P450 3A4, 2C9, 12, 2A6, 2019 or 2D6. However, In vitro studies have shown that Montelukast is a Cytochrome P450 2C8 inhibitor.

Elimination

Montelukast's plasma clearance average is 45 m/min in healthy adults. After taking a dose of Montelukast is marked with radioactive isotope, 86% of radioactive substances are found in feces for 5 days and

In several tests, Montelukast's average plasma sale time varies from 2.7 to 5.5 hours in healthy young people. The pharmacokinetics of Montelukast almost linear at the dose of up to 50 mg. With a dose of 10 mg, once a day, Montelukast accumulates in negligible plasma (14%).

Before taking Montemax 10mg ATCO tablets treat chronic bronchial asthma (1 blister x 14 tablets)

How to use

can use Montemax 10mg at full or hungry.

Dosage

Children from 6 months to 6 years old

Use 1 pack of Montema x 4 mg in the evening.

Children from 6 years old to 14 years old

Use 1 Montema x 5 mg tablet in the evening.

Children aged 15 and over

Use 1 tablet Montema x 10 mg. Every day in the evening.

The therapeutic effect is based on the Montemax 10mg asthma attack parameters within 1 day at the beginning of treatment. It is recommended that patients continue to use Montemax when their asthma attacks are controlled as well as during asthma time.

No dose adjustment in older patients, patients with renal impairment, or patients with mild to medium liver failure.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose? It is unknown whether Montelukast can be eliminated through peritoneal or hemorrhage.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Montemax 10mg, you may experience unwanted effects (ADR).

The following side effects are also recorded, usually occurs mildly and not necessarily stopping the drug.

Sensitive reactions (angioedema, rash, itching, urticaria and very rarely occur in liver leukemia), nightmares, hallucinations, chest drums, sleep, restlessness, restlessness, insomnia, fatigue, increased sweating, dizziness, headache, and dilated pupils.

Nausea, vomiting, indigestion, diarrhea, and abdominal pain.

Nasal congestion, liver enzyme (alanin aminotransferase), AST (Aspartat Aminotransferase).

Increase the trend of bleeding, heart edema.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Montemax 10mg drug is contraindicated in hypersensitivity fields with Montelukast or any ingredient of the drug.

Be cautious when using

The effectiveness of Montemax 10mg in the treatment of unknown acute asthma applications. While reducing the dose of inhaled corticosteroids or oral use simultaneously under the supervision of a doctor, do not immediately replace these drugs with Montemax.

used for children

Montemax 10mg has been studied in children from 6 months to 14 years old (see dosage and use).

Safety and effectiveness of drugs in small patients under 6 months of age has not been determined. Studies show that Montelukast does not affect the growth rate of pediatric patients.

Used for older people

Age does not affect the safety and effectiveness of Montelukast.

The ability to drive and operate machinery

does not affect. However, some rare cases are drowsy or dizzy.

Pregnancy

Montelukast has not been studied in pregnant women. Montelukast should only be used while pregnant when really necessary.

The period of breastfeeding

is not known whether Montelukast whether it is in breast milk or not. Because there are many lactation in breast milk, it is cautious when using Montemax for nursing mothers.

Drug interaction

can use Montemax 10mg with other conventional therapies to prevent and treat chronic asthma. In drug interactive studies, Montelukast's clinical recommendations do not seriously affect the dynamics of the following drugs: Theophylline, Prednisone, Prednisolone, Oral Oral contraceptive (Ethynyl Estradiol/Norethindrone 35/1), Terfenadine, Digoxin and Warfarin.

Be cautious when used with CYP3A4 induction substances such as phenytoin, phenobarbital, rifampicin ... interact with other asthma medications: Montemax 10mg can be added to a asthma regimen for patients.

Reduce the demand for asthma use simultaneously.

Treatment of bronchodilators: Montemax can be added to the treatment regimen for patients who do not control adequately with simple bronchodilators. When clinical response (usually after the first dose), the reduction of bronchodilators can be performed when the patient is tolerated.

Inhaled corticosteroids: Montemax treatment provides additional clinical benefits for patients treated with inhaled corticosteroids. The reduction of corticosteroid dose can be done when the patient is tolerated. Should gradually reduce the dose. In some patients, the inhaled corticosteroid dose can be completely reduced. Can not replace immediately corticosteroid inhalation with Montemax.

Storage

Store in a dry place, less than 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.